Agency to Provide Broader Coverage of Traditionally Approved Drugs to Slow the Progression of Alzheimer’s Disease

Agency to Provide Broader Coverage of Traditionally Approved Drugs to Slow the Progression of Alzheimer’s Disease

Today, the Centers for Medicare and Medicaid Services (CMS) announced that if the Food and Drug Administration (FDA) grants traditional approval to Leqembi, the agency would provide broader Medicare coverage on the same day of approval. The announcement further explains that if the FDA grants traditional approval to other drugs in the same class, those products would also be eligible… (Slifer, June 1, 2023) #Coverage Decisions, #Prescription Drugs